WCG Acquires Trifecta
WCG announced its acquisition of Trifecta Clinical, including its site communication platform InvestigatorSpace, virtual training programs, and safety documentation services.
Dave Young, Trifecta’s Founder and CEO, said, “We’re thrilled to be joining WCG, a company that shares our passion for improving the clinical trial process by delivering impactful solutions to age-old problems. This acquisition was a natural evolution for Trifecta.”
Moving forward, Trifecta will be known as WCG Trifecta, and will retain its leadership structure, along with its headquarters in Los Angeles, and locations in Indianapolis, Philadelphia, and Osaka, Japan.
For the full release, click here.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
